Neuroimmunomodulation in Major Depressive Disorder: Focus on Caspase 1, Inducible Nitric Oxide Synthase, and Interferon-Gamma
Major depressive disorder (MDD) is one of the leading causes of disability worldwide, and its incidence is expected to increase. Despite tremendous efforts to understand its underlying biological mechanisms, MDD pathophysiology remains elusive and pharmacotherapy outcomes are still far from ideal. Low-grade chronic inflammation seems to play a key role in mediating the interface between psychological stress, depressive symptomatology, altered intestinal microbiology, and MDD onset. We review the available pre-clinical and clinical evidence of an involvement of pro-inflammatory pathways in the pathogenesis, treatment, and remission of MDD. We focus on caspase 1, inducible nitric oxide synthase, and interferon gamma, three inflammatory systems dysregulated in MDD. Treatment strategies aiming at targeting such pathways alone or in combination with classical therapies could prove valuable in MDD. Further studies are needed to assess the safety and efficacy of immune modulation in MDD and other psychiatric disorders with neuroinflammatory components.
KeywordsMajor depressive disorder MDD Inflammation Neuroinflammation Caspase 1 Inflammasome T-helper 1 (Th1) Interleukin 1 Inducible nitric oxide synthase Interferon gamma Gut microbiome
Major depressive disorder (MDD) is a psychiatric disorder with significant morbidity, mortality, disability, and economic burden worldwide [1, 2]. In addition to the psychosocial and psychophysical dysfunctions associated with MDD, several conditions are often comorbid, including but not limited to obesity, type-2 diabetes, heart conditions, autoimmune diseases, neurodegenerative disorders, cancer, and intestinal conditions [3, 4, 5, 6, 7]. Multiple hypotheses have been formulated attempting to describe the elusive pathophysiology of MDD, including the monoamine hypothesis, the neurotrophic hypothesis, the glutamate hypothesis, the cytokine (or macrophage) hypothesis, and the microbiota-inflammasome hypothesis [8, 9, 10, 11, 12, 13]. However, no single hypothesis seems to fully explain the onset, course, and remission of the disease. To complicate matters further, antidepressant drugs present numerous side effects and are effective only in a subset of patients [14, 15, 16]. Newer therapeutic strategies involve drugs acting on neuroplasticity-related pathways, gut microbiome modulation, and deep brain stimulation surgery [17, 18, 19]. Nevertheless, the quest for a better understanding of the molecular underpinnings of this disease represents an essential step in the identification of efficacious therapeutic strategies that could target the causal biological mechanisms of MDD.
Emerging evidence suggests that dysregulated neuro-immune pathways underlie depressive symptomatology in at least a subset of MDD patients [2, 20, 21, 22, 23, 24, 25]. Three crucial inter-linked networks seem to influence the bidirectional communication between the brain, the immune system, and the intestinal microbiome, namely (a) increased oxidative stress, driven by nitric oxide (NO) overproduction, (b) chronic inflammation, driven by caspase 1 (CASP1), and Nod-like receptors family pyrin domain containing 3 (NLRP3) inflammasome over activation, and (c) central nervous system (CNS) T cell-helper 1 (Th1) lymphocyte infiltration, driven by interferon-gamma (IFNG). These three networks are strictly interlinked and present several levels of reciprocal regulation. For example, NO is a critical negative modulator of the NLRP3 inflammasome, while being necessary for IFNG-mediated suppression of interleukin-1 beta (IL1B) processing [26, 27]. Moreover, CASP1 regulates IFNG production via producing IL18, while IFNG modulates the CASP1 system . Similarly, transcription of inducible nitric oxide synthase (NOS2) can be activated by IFNG . Lastly, CASP1 is involved in the epigenetic regulation of NOS2 . These multidirectional interactions suggest the importance of observing and therapeutically approaching these pathways as a whole rather than as insular entities. The possible involvement of these three systems in MDD is briefly summarized here and will be described in detail throughout this review.
Reactive oxygen species (ROS) are produced during cell metabolism, and are largely quenched by the endogenous antioxidant machinery . However, excess of oxidative products can elicit oxidative stress and cause protein, lipid, and/or DNA damage . Preclinical and clinical studies suggest that chronic stress exposure is associated with increased ROS production [33, 34, 35, 36, 37, 38, 39, 40]. One of the free radicals produced during psychological stress is NO, mainly by NOS2 . Inflammatory factors play key roles in tissue repair and in defense against pathogens [42, 43]. However, pathological activation of inflammatory cascades caused by stress and other insults can alter brain function and increase the likelihood of developing MDD and comorbid conditions [44, 45, 46]. CASP1, a protease that in the NLRP3 inflammasome renders the mature forms of IL1B and IL18, is also activated by stress [47, 48]. It has been shown that reactive T cells infiltrate the brain where they produce pro-inflammatory cytokines in response to CNS antigens . Lastly, IFNG is a powerful inducer of indoleamine 2,3-dioxygenase 1 (IDO1), which degrades tryptophan increasing kyneurine and quinolinic acid, leading to hyposerotonergia and hyperglutamatergia, involved in MDD [9, 50, 51].
Recently, the role of the gut microbiome in mental health and illness has come to the forefront in psychiatry [52, 53]. Increasing evidence suggests the existence of a gut-brain-axis, a communication network that integrates brain and gut function, which plays a fundamental role in health and disease . Such communication occurs via the endocrine and immune systems, the vagus nerve, and the bacterial metabolome [55, 56, 57]. It is becoming clear that the gut-brain-axis is an entity directly involved in modulating stress systems like the hypothalamic-pituitary-adrenal (HPA) axis, via its effects on the immune and endocrine systems, which affect behavior and mood and that can lead to MDD [53, 58, 59]. Given its central role in modulating immune processes and brain function, and given that MDD is characterized by altered gut microbiome composition, consensus is growing that manipulating the gut microbiota could represent a therapeutic tool in the treatment of MDD [19, 60]. In this review, we will summarize the pre-clinical and clinical evidence supporting the involvement of CASP1, NOS2, and IFNG in the pathophysiological processes underlying depressive symptomatology.
Communication Between the Brain, the Immune System, and the Gut Microbiome
Although the CNS is considered to have its “own” immune system, independent from the peripheral immune system, it is accepted that the two constantly communicate and cooperate, that the CNS is involved in regulating immunity, and that immune responses in the periphery lead to behavioral changes [66, 67].
Stress-mediated upregulation of pro-inflammatory cytokines [such as IL1, IL6, tumor necrosis factor (TNF), and IFNG] leads to endocrine and neurochemical responses, such as sympathetic nervous system (SNS), hypothalamic-pituitary-adrenal (HPA) axis, and microglial activation. SNS stimulation triggers epinephrine and norepinephrine release in the locus coeruleus and adrenal medulla, which result in an upregulation of pro-inflammatory signaling. SNS activation in response to stress pushes the CNS to “steer” immunity towards pro-inflammatory and antiviral responses . At the same time, norepinephrine modulates pro-inflammatory cytokines transcription via beta-adrenergic receptor stimulation .
This leads to HPA axis activation by hypothalamus-secreted corticotropin releasing hormone (CRH) and arginine vasopressin (AVP). CRH stimulates adrenocorticotropic hormone (ACTH) release from the pituitary gland, which stimulates glucocorticoids release by the adrenal gland. Glucocorticoids interact with the glucocorticoid receptor (NR3C1) and the mineralocorticoid receptors (NR3C2), activating anti-inflammatory cascades and inhibiting Th1-driven pathways. This upregulates anti-inflammatory gene expression to avoid side effects [69, 70, 71, 72, 73]. The gut microbiome modulates HPA axis processes. In fact, germ-free rodents have greater plasma ACTH and corticosterone spikes compared to wild-type in response to stressors, while displaying altered anxiety-like behavior . This exaggerated response can be reversed by early stage (but not later stage) recolonization with Bifidobacterium infantis . Interestingly, the brain regions presenting the highest concentrations of pro-inflammatory cytokines are the prefrontal cortex, the hypothalamus, and the hippocampus, areas involved in cognition, mood, and antidepressant response [75, 76].
Increased concentrations of brain cytokines trigger the activation of microglia, immune cells inhabiting the brain parenchyma, representing chief innate immune cells in the brain [67, 77]. Depending on the temporal and qualitative cytokine profile, stress-induced microglial activation can either stimulate neuroprotection or neurodegeneration . Not surprisingly, the gut microbiome modulates microglia homeostasis and maturation, while reduced gut microbiome complexity impairs microglia function . Altogether, these stress-induced inflammatory events alter neurotransmitter systems, such as serotonin (5HT) and dopamine (DA), exacerbating depressive symptoms [80, 81]. Interestingly, the gut microbiome is also involved in neurotransmitter modulation, either via producing neurotransmitters, consuming them, or responding to them . This raises the intriguing possibility that by altering gut microbiota composition, it might become possible to modulate neurotransmitter systems in pathological states, including MDD (Reviewed by ).
Glucocorticoids have the effect of restoring homeostasis . However, in MDD, the HPA axis can become hyperactive. This phenomenon is underlined by increased cortisol, blunted ACTH response to CRH, glucocorticoid resistance, impairment in gluco- and mineral-corticoid signaling, and enlargement of the pituitary and adrenal glands [84, 85, 86, 87, 88]. Antidepressant drugs normalize the HPA axis and enhance the expression and function of corticosteroids [89, 90]. Peripheral cytokines can cross the blood-brain barrier (BBB) via (a) CNS lymphatic vessels, (b) active transport and a leaky or compromised BBB, (c) crossing at circumventricular organs, and (d) binding to receptors in the blood vessels that course through the brain [91, 92, 93, 94]. Moreover, cytokines can affect brain function indirectly, through vagal nerve activation or by binding to cell-surface proteins found in brain endothelial cells [91, 93, 95, 96].
Cytokines can be produced in the gut in response to bacterial virulence factors (such as LPS), and in response to bacterial translocation to physiologically sterile enteric compartments (“leaky gut”) . It was proposed that the leaky gut phenomenon contributes to MDD . In fact, stress is known to compromise gut epithelial barrier integrity, allowing gut bacteria to access the enteric nervous system and immune cells . Intestinal inflammation is a major contributor to changes in gut microbiome composition and function that are associated with disease (Reviewed in ). IFNG triggers the production of hydrogen peroxide and the epithelial expression of NOS2, which elevates the concentration of NO, in turn favoring the expansion of facultative anaerobic clades and hindering enterocyte proliferation [100, 101]. The resulting inflamed intestine perpetuates the production of pro-inflammatory cytokines and inflammogenic microbial metabolites, which affect brain processes and precipitate MDD onset while increasing the likelihood of comorbid conditions [99, 102]. Lastly, cytokines are produced de novo in the brain in response to stress [103, 104, 105].
Psychoneuroimmune Interactions and the Cytokine Hypothesis of Depression
Psychoneuroimmunology studies the reciprocal interactions between behavioral traits and the immune system, mediated by the nervous and endocrine systems . In MDD, increasing evidence suggests that the communication networks existing between the microbiota and the nervous, immune, and endocrine systems lie at the crossroads of psychosocial stress, onset of depressive symptomatology and antidepressant response . Studies suggest anti-inflammatory, endocrine,- and entero-regulatory effects of antidepressants, antidepressant effects of anti-inflammatory medications, and differential responses to antidepressants driven by polymorphisms in inflammation-related genes [108, 109, 110, 111, 112]. With regard to the immune players of such communication, cytokines have gained increasing attention over the past 20 years. Cytokines are pleiotropic signaling molecules with immunomodulatory function expressed constitutively and on-demand in the periphery and in the CNS and have been associated in at least a subset of patients with onset, course, and severity of neuropsychiatric disorders, as well as with the response to therapeutic drugs [113, 114, 115, 116, 117, 118, 119, 120, 121, 122].
Exposure to psychological stressors primes the immune system towards the creation of a pro-inflammatory environment in the brain, a phenomena called sterile inflammation, which prepares the CNS and the body to trigger a potential full-blown immune response [123, 124]. While this program is essential for coping with the stressor and restoring homeostasis, it requires high amounts of energy and has collateral damage potential. In fact, repeated or chronic stress exposure results in a sustained inflammatory milieu in the brain which can lead to the development of MDD and comorbid illnesses [23, 125].
These lines of evidence led to the “cytokine hypothesis” (or “macrophage hypothesis”) of depression, which proposes that cytokines and an out-of-balance brain-immune communication are key MDD milestones [126, 127, 128, 129, 130]. This hypothesis is supported by mounting evidence: (a) illnesses characterized by chronic inflammatory responses (e.g., type-1 diabetes and systemic lupus erythematous) are associated with increased depression rates [4, 6], (b) administration of pro-inflammatory cytokines as a therapeutic strategy (e.g., IFNA administration in cancer and hepatitis-C) induces a dose-response depressive symptomatology and molecular features of MDD [131, 132, 133, 134, 135], and (c) pro-inflammatory cytokines administration in vivo induces sickness or depressive-like behavior [22, 136]. Lastly, polymorphisms in inflammation-related genes associate with increased MDD susceptibility and differential antidepressant response . These layers of evidence suggest that neuroinflammation is involved in MDD, providing fertile ground to investigate diagnostic and therapeutic opportunities in neuro-immuno-psychiatry.
Major Depression and Dysregulated Inflammatory Pathways
Cytokine Signaling and Nitrosative Stress
Oxidative stress is involved in MDD pathophysiology . Stress exposure leads to ROS upregulation via cytokine-induced NOS2 induction, an event that heightens the overall oxidative stress, activating a feedback loop (co-activation state) that produces more cytokines . Oxidative stress is characterized by the generation of ROS, which contributes to protein and DNA damage, and can result in irreversible brain function changes, leading to neurodegeneration and cognitive impairments . Oxidative processes are gaining attention in psychiatry, since an expanding body of research suggests the involvement of these pathways in MDD [24, 40, 138, 157, 158, 159].
The involvement of oxidative and nitrosative stress in MDD is confirmed by the increased oxidative (such as NO, arachidonic acid, malondialdehyde, and 8-hydroxy-2-deoxyguanosine) and nitrosative (such as immunoglobulin (M IgM)- antibodies directed against phosphatidylitol and nitro-bovine serum albumin) stress markers in MDD patients, together with decreased levels of antioxidants (such as vitamins C and E) [160, 161, 162, 163, 164]. Interestingly, the concentration of oxidative stress markers correlates with depression severity and chronicity, as well as with antidepressant response [40, 138, 161, 165]. Accordingly, some antioxidant compounds have antidepressant properties, and antidepressants (such as paroxetine) partially reverse oxidative damage by enhancing the protective antioxidant status following stress [158, 166, 167, 168].
Of crucial importance for this work, the NO system is being investigated in MDD, because NO levels are increased in MDD and in animal models of stress, while NO inhibition has antidepressant effects (discussed in detail below) [37, 164, 169, 170, 171]. Increased levels of oxidative and nitrosative molecules can easily damage neurons, since they are particularly vulnerable to free radicals . Moreover, the brain presents lower concentrations of antioxidants compared to other organs, making it more susceptible to free radicals . Unsurprisingly, some areas (i.e., the subfields Cornu Ammonis (CA)1) and CA4) of the hippocampus (a brain region involved in mood regulation and adult neurogenesis) are the most sensitive to oxidative damage .
The Role of Caspase 1 in MDD
As mentioned above, stress triggers “sterile inflammation,” initiated by endogenous danger signal recognition, termed damage-associated molecular patterns (DAMPs), by glial cells, macrophages, and oligodendrocytes [124, 181, 182]. DAMPS are nuclear, cytosolic, mitochondrial, or extracellular molecules normally hidden from the immune system that upon activation are exposed and released in the extracellular space, where they stimulate an immune activation [124, 183]. In line with this understanding, increased levels of DAMPs have been found in rodent blood and hippocampus following stress exposure [103, 184].
Once released in the extracellular space, DAMPs function as alarm signals, alerting immune cells through pattern recognition receptors, to get ready for a potential full-blown immune response [182, 185, 186]. It has been hypothesized that such processes could represent an adaptive characteristic of the acute stress response; for example, if an animal were running away from a predator and were wounded during the chase, it might have better chances of surviving if its immune system were primed and ready to respond . Another theory, one that places this mechanism in a modern context, suggests that such stress responses are activated when an individual is exposed to social evaluation, rejection, isolation, exclusion or conflict, possibly due to the potentially physically harmful significance of such social situations throughout history .
Together, DAMPs activation and release induce the transcriptional upregulation of a number of immune genes, such as IL1B, IL6, and TNF. This results in the creation of a pro-inflammatory milieu in the brain and periphery, and in the activation of the afferent nerves, which in turn leads to de novo production of pro-inflammatory cytokines in the brain and culminates with the onset of depressive-like behavior [22, 136, 189].
Further, DAMP activation results in the assembly of inflammasomes [186, 190] A peculiar role is played by the NLRP3 inflammasome, that consists of the NLRP3 protein, the adaptor apoptosis-associated speck-like protein containing a CARD (ASC), and the cysteine-protease CASP1 . Upon inflammasome assembly, the inactive procaspase 1 zymogen is proteolitically cleaved into the enzymatically active heterodimer [191, 192]. In turn, activated CASP1 cleaves pro-IL1B and pro-IL18 into their mature, releasable, bioactive isoforms [47, 193]. Increased circulating levels of IL1B activate the HPA axis, which increases glucocorticoids production. 
Clinical evidence of CASP1 involvement in MDD
Increased CASP1 and NLRP3 transcription in PBMC (peripheral blood mononuclear cells) from MDD patients.
Increased NLRP3 protein levels in PBMC from MDD patients.
Increased IL1B and IL18 in serum from MDD patients which positively correlate with BDI (Beck Depression Inventory) score.
Antidepressant treatment decreased NLRP3 and CASP1 transcription in PBMC from MDD patients.
Antidepressant treatment decreased IL1B and IL18 in serum from MDD patients.
IL18 is increased in MDD patients.
IL18 is increased in patients with panic disorder.
IL18 promoter variants (rs187238 and rs1946518) associate with higher IL18 transcription and increased susceptibility to MDD in patients exposed to stressful events.
Polymorphisms in the IL33 gene (rs11792633 and rs7044343) moderate the correlation between history of childhood abuse and recurrent depression in women.
Patients with recurrent depression have higher peripheral IL33
Pre-clinical evidence of CASP1 involvement in animal models of MDD
Chronic unpredictable mild stress (CUMS) increases PFC (prefrontal cortex) CASP1 activation and NLRP3 and IL1B transcription and protein level.
Antidepressant treatment decreases PFC NLRP3 protein level and IL1B transcription and protein level.
LPS-induced depressive-like behavior increases brain CASP1, NLRP3, and ASC transcription, and IL1B transcription and protein level.
Pre-treatment with an NLRP3 inhibitor (Ac -YVAD-CMK) ameliorates depressive-like behavior.
CUMS increases hippocampal and serum Il1b and increases hippocampal CASP1 activity and NLRP3 and ASC protein levels.
Pretreatment with the NLRP3 inflammasome inhibitor VX-765 decreases serum and hippocampal IL1B protein levels and decreases depressive-like behavior.
CASP1−/− mice display decreased depressive- and anxiety-like behaviors, while being protected by the exacerbation of depressive-like behavior following chronic stress.
The CASP1 inhibitor minocycline prevents the exacerbation of depressive-like behavior following stress.
Minocycline triggers the expansion of bacterial populations with anti-inflammatory effects.
CUMS increase hippocampal IL1B.
IL1R−/− mice do not display CUMS-induced behavioral or neuroendocrine changes.
IL1R−/− mice do not display CUMS-induced decreases in neurogenesis.
IL1B exogenous administration mimics CUMS-induced depressive-like symptoms.
Stress and Il1b administration suppress hippocampal cell proliferation.
IL1R1 blockade blocks the antineurogenic effects of stress.
IL18−/− mice display decreased depressive- and anxiety-like behaviors.
IL18 is involved in stress-induced microglial activation while contributing to dopaminergic degeneration.
Acute stress increases IL33 expression in the paraventricular nucleus of the hypothalamus and in the prefrontal cortex.
CASP1−/− mice have the same behavioral and inflammatory responses to systemic lipopolysaccharide (LPS) administration as wild-type (wt) mice, but are resistant to the development of depressive-like behavior and to pro-inflammatory cytokines increase following intracerebroventricular LPS administration . Moreover, CASP1−/− mice are resistant to lethal LPS doses and have decreased levels of inflammation-induced brain and systemic transcription [195, 196, 197]. Significantly for this review, CASP1 and the NLRP3 inflammasome are involved in the development of depressive-like behavior in stress models and are increased in MDD [61, 173]. At the same time, pathological shifts in gut microbiota composition and leaky gut trigger an increase in pro-inflammatory signaling, which increases the risk of developing depressive symptomatology and comorbid illnesses . Such evidence has led to the formulation of the microbiota-inflammasome hypothesis of major depression and comorbid systemic illnesses . This hypothesis suggests that pathological gut microbiome shifts upregulate pro-inflammatory pathways exacerbating depressive symptomatology and increasing the likelihood of developing comorbid conditions .
IL1B binds to the interleukin-1 receptor (IL1R1), which results in the activation of many acute-phase inflammation genes, such as NOS2, IL6, and cyclooxygenase type 2 [192, 199]. Recently, it was suggested that NLRP3 inflammasome activation mediates IL1B orchestrated inflammation (that results in depressive-like behavior) in the prefrontal cortex following stress, and that fluoxetine reverses such changes [173, 175]. Accordingly, mice lacking the IL1 receptor are resistant to developing depressive-like behavior following chronic stress while being protected against the decrease in neurogenesis observed in wt mice following stress [176, 177].
IL1A shares features with IL1B and is an equally potent pro-inflammatory cytokine . However, IL1A also presents differences to IL1B. For example, unlike the IL1B precursor which is not active, both the pro-IL1A and the cleaved IL1A are active ligands of the IL1R1 . Moreover, while IL1B is released, IL1A can be secreted or membrane-bound, although the factors that control such translocation have not been fully elucidated yet [207, 209]. Finally, while IL1B is produced on-demand in immune cells, IL1A is constitutively expressed in a variety of cell types but can be produced by immune cells in response to insults . Interestingly, IL1A-mediated activation of p38-MAPK inhibits NR3C1 function, suggesting that the mechanism conferring glucocorticoid resistance in MDD could be associated with IL1A . To the best of our knowledge, no studies have investigated anxiety- and depressive-like phenotypes in IL1A−/− mice.
IL18 is a prototypical Th1 cytokine for its ability to stimulate IFNG activity, and it is expressed in macrophages and dendritic cells . Circulating IL18 increases during stress and in response to HPA axis activation . IL18 binds to the IL18 receptor (IL18R) activating p38-MAPK, c-Jun N-terminal kinase, and NFKB1 cascades, which potentiate antimicrobial and antiviral immunity [214, 215]. Although IL18 is known for its ability to promote both Th1- and Th2-related inflammatory responses, its predominant role in enhancing Th1 activity makes this cytokine a candidate therapeutic target in Th1-related inflammatory and autoimmune diseases, including MDD .
IL18 is increased in MDD and in panic disorder [62, 63]. IL18 gene promoter variants (rs187238 and rs1946518) associate with higher IL18 transcription and increased MDD susceptibility in patients exposed to stressful events. IL18−/− mice have decreased IFNG production and impaired natural killer cell activity and abnormal Th1 responses . Moreover, IL18−/− mice display decreased depressive- and anxiety-like behavior, as well as gene expression changes across various brain regions [178, 217]. In addition, immobilization stress in mice induces pro-IL18 via ACTH and a superoxide-activated CASP1 pathway . Given that IL6 is not induced in response to stress in IL18−/− mice, it seems that IL18 mediates stress-induced IL6 upregulation . Lastly, IL18 is involved in stress-induced microglial activation in rodents while contributing to dopaminergic degeneration [179, 180].
IL33 has alarmin and transcription factor roles and triggers predominantly Th2 responses (such as the induction of IL4, IL5, IL13, and anti-inflammatory gene expression) . Like other members of the IL1 family, IL33 can be beneficial or detrimental, depending on its spatio-temporal expression. IL33 is constitutively expressed and localized in the cytoplasm. However, if a barrier is breached and IL33 is released from destroyed cells, it acts as an alarmin upon binding the IL33 receptor (ST2) . The signaling cascade in response to ST2 activation modulates hundreds of genes with a pattern that resembles that of IL1R1 activation .
Two single nucleotide polymorphisms in the IL33 gene (rs11792633 and rs7044343) moderate the correlation between history of childhood abuse and recurrent depression in women . Moreover, patients with a history of recurrent depression have greater peripheral levels of IL33 and IL1B . Finally, IL33 is expressed in the paraventricular nucleus of the hypothalamus and in the prefrontal cortex of rats exposed to acute stress, suggesting that stress induces IL33 expression in those brain regions .
The Role of Inducible Nitric Oxide Synthase in MDD
NO is a small intercellular and intracellular signaling molecule with a very short half-life (3–6 s) that freely diffuses across cell membranes. NO plays important roles in the brain modulating pathways such as neurogenesis, neurotransmission, synaptic plasticity, learning, and pain . NO also regulates emotional and cognitive processes, suggesting that it could be involved in the etiology of MDD and anxiety disorders . Three isoforms of the NOS enzyme produce NO: NOS2, neuronal (NOS1), and endothelial (NOS3), all of which have specific spatio-temporal patterns of regulation. In this review, we will focus on the inducible isoform since it is considered the most relevant to MDD.
Clinical evidence of NOS2 involvement in MDD
Increased plasma nitric oxide (NO) metabolites in suicide attempters.
Increased plasma NO metabolites in depressed suicide attempters.
Increased plasma NO metabolites in suicide attempters.
Higher plasma NO levels were related to lower suicide lethality and lower depression severity.
Increased plasma nitrate concentration in MDD patients.
Increased NOS2 transcription in peripheral blood of MDD patients.
The polymorphism (-1026C/A) in the NOS2 promoter is associated with the risk of recurrent depressive disorder.
IgM levels against NO adducts are elevated in MDD patients, suggesting an autoimmune-like response.
The antidepressant paroxetine is a NOS2 inhibitor.
Pre-clinical evidence of NOS2 involvement in animal models of MDD
NOS2 inhibitors augment the efficacy of serotonin reuptake inhibitors in the forced swim test.
NOS2 is increased in the hippocampus and cerebral cortex following stress.
NOS2 inhibition results in antidepressant-like effects in rodents.
The dopamine reuptake inhibitor bupropion modulates the NO system.
The architecture of the NOS2 promoter region suggests that this gene has a tight and complex pattern of transcriptional control since it is rich in positive and negative regulatory regions, and it is responsive to many transcription factors, cytokines, and bacterial by-products . NOS2 is synthesized on-demand in macrophages and microglia . In fact, whereas there is no detectable physiological NOS2 expression in the brain, a profound transcriptional upregulation of the NOS2 gene can be observed in response to traumatic events such as ischemia and systemic inflammation, most likely through activation of the NOS2 promoter by inflammation-related molecules [29, 39, 196, 228, 229]. Following induction, NOS2 produces NO continuously until the proteasome degradation pathway inactivates the enzyme .
Several studies have targeted the NO system in pre-clinical MDD research, yielding promising results. For example, NO decreases norepinephrine production, decreases nitrate and nitrite levels in the hippocampus and cerebral cortex, and decreases serotonin turnover in the frontal cortex [231, 232, 233]. Moreover, NO inhibits the dopamine transporter, indirectly increasing the availability of inter-synaptic dopamine . Finally, several molecules such as bupropion (a norepinephrine-dopamine reuptake inhibitor), venlafaxine (a serotonin-norepinephrine reuptake inhibitor), mementine (an NMDA receptor antagonist), and berberine (a plant alkaloid), all of which produce antidepressant-like effects, modulate this signaling pathway .
It is accepted that anaerobic bacteria in the gut prevent the expansion of facultative anaerobic bacteria, at least partially by limiting the host-mediated production of oxygen and nitrate . Antibiotic-mediated disruption of the gut microbiota increases the production of host nitrate in the gut . This allows an expansion of the facultative anaerobic Enterobacteriaceae, which includes potentially pathogenic gram-negative bacteria, such as Escherichia coli (this effect is likely not to be limited to E. coli, although the latter has been the focus of investigation to date). These bacteria produce the virulence molecule LPS, which triggers depressive-like behavior and increases serotonin degradation in the brain [237, 238]. This alteration is mediated by NOS2; therefore, its inhibition prevents E. coli overgrowth . Therefore, rectifying aberrant NO signaling could have a therapeutic role in altered gut microbiology-induced depressive symptoms . Accordingly, stimulation of colonic epithelial cancer cells by IFNG induces NOS2-mediated NO production, while butyrate (one of the main anti-inflammatory short chain fatty acids (SCFAs)) blunts NO production . This result suggests that a diet rich in substrates for SCFAs production could have antidepressant-like effects via its repercussions on gut microbiome composition and inflammatory processes. Together, these findings suggest that modulation of the NO system could represent a useful approach in treating MDD and in keeping of a healthy gut microbiome.
The Role of Interferon-Gamma in MDD
IFNG is a pleiotropic soluble cytokine which orchestrates cellular programs via transcriptional and translational gene control. IFNG is produced by immune cells such as lymphocytes, cytotoxic lymphocytes, B cells, and antigen-presenting cells [240, 241]. The IFNG receptor (IFNGR) is expressed on almost all cell types, and its activation triggers the janus kinase 1 and 2 (JAK1/2) signal transducer and activator of transcription 1 (STAT1) pathway, as well as additional pathways, such as the extracellular-signal-regulated-kinase 1/2 (ERK1/2) [242, 243]. Activation of the IFNGR results in the transcription of genes with IFNG-stimulated response elements (ISREs) within their promoter region until STAT1 dissociates following complete dephosphorylation within 1–2 h [244, 245]. The genes transcribed in response to IFNGR activation are at least 200, together with many micro RNAs and long non-coding RNAs  (for a database see ). At the same time, after IFNGR stimulation, the secondary transcription factors IRF1, IRF2, and interferon consensus sequence binding protein are upregulated. This in turn results in the transcriptional induction of a subset of inflammatory-related genes such as NOS2 (stimulated by IRF1) and guanylate-binding protein. Finally, IFNG can activate and be activated by CASP [248, 249, 250, 251].
Clinical evidence of IFNG involvement in MDD
Ex vivo PBMC from MDD patients display increased IFNG production upon stimulation.
Transcriptional levels of IFNG correlate with depressive symptomatology in multiple sclerosis patients.
The antidepressants clomipramine, sertraline, and trazodone suppress IFNG production.
A polymorphism in the IFNG gene (CA repeat, rs3138557) correlates with lower serum tryptophan and higher kyneurine increasing MDD likelihood.
The high producer T allele + 874(T/A) polymorphism (rs2430561) in the IFNG gene has been associated with increased IDO1 activity and increased MDD likelihood.
Pre-clinical evidence of IFNG involvement in animal models of MDD
IFNG−/− mice display decreased anxiety- and depressive-like behaviors as well as heightened emotionality.
IFNG−/− mice display increased serotonergic and noradrenergic metabolite accumulation.
IFNG−/− mice display increased plasma corticosterone levels.
IFNG−/− mice display decreased hippocampal neurogenesis.
IFNG−/− mice display decreased levels of nerve growth factor in the prefrontal cortex.
IFNG−/− mice have attenuated monoamine, corticoid, and cytokine alterations in response to stressors.
IFNG signaling promotes leaky gut and bacterial translocation. In fact, in vitro experiments have highlighted that low-dose IFNG dramatically increases the translocation of opportunistic pathogens, and high-doses disrupt tight junctions . Lastly, IFNG levels affect the representation of specific bacterial species while being up- or downregulated by specific commensals . For example, the degradation of tryptophan to the metabolite tryptophol inhibits IFNG production, while IFNG levels dictate the presence and expansion of specific bacterial taxa . Given this evidence for an involvement of IFNG in pathways relevant to depressive symptoms and gut dysbiosis, targeting IFNG and/or its receptor could hold potential in the quest for novel MDD therapies.
Conclusions and Future Directions
Convergent pre-clinical and clinical evidence points towards an involvement of central and peripheral inflammatory pathways and the gut microbiome in the response to psychological stressors and in the onset, treatment, and remission of MDD. Future randomized controlled trials should investigate the safety and efficacy of decreasing CASP1-, NOS2,- and IFNG-mediated pathways in MDD patients. Reduced activity of those pro-inflammatory mediators could be achieved via pharmacological inhibition or gut microbiome manipulation. The latter approach can involve diet, probiotics supplementation, and fecal microbiota transplantation. This could lead to the development of novel antidepressant strategies acting upon the dysregulated inflammatory milieu observed in MDD. Because inhibiting such pathways might hinder physiological immune processes, particular care should be taken when developing immunomodulatory and gut microbiota-directed therapies.
Compliance with Ethical Standards
Conflict of Interest
The authors declare that they have no conflicts of interest.
- 2.Maes M, Leonard B, Fernandez A, Kubera M, Nowak G, Veerhuis R, Gardner A, Ruckoanich P et al (2011) (Neuro)inflammation and neuroprogression as new pathways and drug targets in depression: From antioxidants to kinase inhibitors. Prog Neuro-Psychopharmacol Biol Psychiatry 35(3):659–663. https://doi.org/10.1016/j.pnpbp.2011.02.019 CrossRefGoogle Scholar
- 15.Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, Niederehe G, Thase ME et al (2006) Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 163(11):1905–1917. https://doi.org/10.1176/ajp.2006.163.11.1905 CrossRefPubMedPubMedCentralGoogle Scholar
- 16.Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L, Norquist G, Howland RH et al (2006) Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 163(1):28–40. https://doi.org/10.1176/appi.ajp.163.1.28 CrossRefPubMedPubMedCentralGoogle Scholar
- 17.Dandekar MP, Fenoy AJ, Carvalho AF, Soares JC, Quevedo J (2018) Deep brain stimulation for treatment-resistant depression: an integrative review of preclinical and clinical findings and translational implications. Mol Psychiatry 23(5):1094–1112. https://doi.org/10.1038/mp.2018.2 CrossRefPubMedPubMedCentralGoogle Scholar
- 20.Vogelzangs N, Duivis HE, Beekman AT, Kluft C, Neuteboom J, Hoogendijk W, Smit JH, de Jonge P et al (2012) Association of depressive disorders, depression characteristics and antidepressant medication with inflammation. Transl Psychiatry 2:e79. https://doi.org/10.1038/tp.2012.8 CrossRefPubMedPubMedCentralGoogle Scholar
- 24.Leonard B, Maes M (2012) Mechanistic explanations how cell-mediated immune activation, inflammation and oxidative and nitrosative stress pathways and their sequels and concomitants play a role in the pathophysiology of unipolar depression. Neurosci Biobehav Rev 36(2):764–785. https://doi.org/10.1016/j.neubiorev.2011.12.005 CrossRefPubMedPubMedCentralGoogle Scholar
- 26.Mishra BB, Rathinam VA, Martens GW, Martinot AJ, Kornfeld H, Fitzgerald KA, Sassetti CM (2013) Nitric oxide controls the immunopathology of tuberculosis by inhibiting NLRP3 inflammasome-dependent processing of IL-1beta. Nat Immunol 14(1):52–60. https://doi.org/10.1038/ni.2474 CrossRefPubMedPubMedCentralGoogle Scholar
- 30.Buzzo CL, Medina T, Branco LM, Lage SL, Ferreira LC, Amarante-Mendes GP, Hottiger MO, De Carvalho DD et al (2017) Epigenetic regulation of nitric oxide synthase 2, inducible (Nos2) by NLRC4 inflammasomes involves PARP1 cleavage. Sci Rep 7:41686. https://doi.org/10.1038/srep41686 CrossRefPubMedPubMedCentralGoogle Scholar
- 31.Karihtala P, Soini Y (2007) Reactive oxygen species and antioxidant mechanisms in human tissues and their relation to malignancies. APMIS 115(2):81–103. https://doi.org/10.1111/j.1600-0463.2007.apm_514.x CrossRefPubMedPubMedCentralGoogle Scholar
- 33.Patki G, Solanki N, Atrooz F, Allam F, Salim S (2013) Depression, anxiety-like behavior and memory impairment are associated with increased oxidative stress and inflammation in a rat model of social stress. Brain Res 1539:73–86. https://doi.org/10.1016/j.brainres.2013.09.033 CrossRefPubMedPubMedCentralGoogle Scholar
- 61.Alcocer-Gomez E, de Miguel M, Casas-Barquero N, Nunez-Vasco J, Sanchez-Alcazar JA, Fernandez-Rodriguez A, Cordero MD (2014) NLRP3 inflammasome is activated in mononuclear blood cells from patients with major depressive disorder. Brain Behav Immun 36:111–117. https://doi.org/10.1016/j.bbi.2013.10.017 CrossRefPubMedPubMedCentralGoogle Scholar
- 62.Prossin AR, Koch AE, Campbell PL, McInnis MG, Zalcman SS, Zubieta JK (2011) Association of plasma interleukin-18 levels with emotion regulation and mu-opioid neurotransmitter function in major depression and healthy volunteers. Biol Psychiatry 69(8):808–812. https://doi.org/10.1016/j.biopsych.2010.10.014 CrossRefPubMedPubMedCentralGoogle Scholar
- 64.Haastrup E, Bukh JD, Bock C, Vinberg M, Thorner LW, Hansen T, Werge T, Kessing LV et al (2012) Promoter variants in IL18 are associated with onset of depression in patients previously exposed to stressful-life events. J Affect Disord 136(1–2):134–138. https://doi.org/10.1016/j.jad.2011.08.025 CrossRefPubMedPubMedCentralGoogle Scholar
- 74.Sudo N, Chida Y, Aiba Y, Sonoda J, Oyama N, Yu XN, Kubo C, Koga Y (2004) Postnatal microbial colonization programs the hypothalamic-pituitary-adrenal system for stress response in mice. J Physiol 558(Pt 1):263–275. https://doi.org/10.1113/jphysiol.2004.063388 CrossRefPubMedPubMedCentralGoogle Scholar
- 76.Felger JC, Lotrich FE (2013) Inflammatory cytokines in depression: neurobiological mechanisms and therapeutic implications. Neuroscience 246:199–229. https://doi.org/10.1016/j.neuroscience.2013.04.060 CrossRefPubMedPubMedCentralGoogle Scholar
- 79.Erny D, Hrabe de Angelis AL, Jaitin D, Wieghofer P, Staszewski O, David E, Keren-Shaul H, Mahlakoiv T et al (2015) Host microbiota constantly control maturation and function of microglia in the CNS. Nat Neurosci 18(7):965–977. https://doi.org/10.1038/nn.4030 CrossRefPubMedPubMedCentralGoogle Scholar
- 90.Fitzgerald P, O'Brien SM, Scully P, Rijkers K, Scott LV, Dinan TG (2006) Cutaneous glucocorticoid receptor sensitivity and pro-inflammatory cytokine levels in antidepressant-resistant depression. Psychol Med 36(1):37–43. https://doi.org/10.1017/S003329170500632X CrossRefPubMedPubMedCentralGoogle Scholar
- 98.Maes M, Kubera M, Leunis JC, Berk M, Geffard M, Bosmans E (2013) In depression, bacterial translocation may drive inflammatory responses, oxidative and nitrosative stress (O&NS), and autoimmune responses directed against O&NS-damaged neoepitopes. Acta Psychiatr Scand 127(5):344–354. https://doi.org/10.1111/j.1600-0447.2012.01908.x CrossRefGoogle Scholar
- 102.Dopkins N, Nagarkatti PS, Nagarkatti M (2018) The role of gut microbiome and associated metabolome in the regulation of neuroinflammation in multiple sclerosis and its implications in attenuating chronic inflammation in other inflammatory and autoimmune disorders. Immunology 154(2):178–185. https://doi.org/10.1111/imm.12903 CrossRefPubMedPubMedCentralGoogle Scholar
- 103.Weber MD, Frank MG, Tracey KJ, Watkins LR, Maier SF (2015) Stress induces the danger-associated molecular pattern HMGB-1 in the hippocampus of male Sprague Dawley rats: a priming stimulus of microglia and the NLRP3 inflammasome. J Neurosci 35(1):316–324. https://doi.org/10.1523/JNEUROSCI.3561-14.2015 CrossRefPubMedPubMedCentralGoogle Scholar
- 105.Iwata M, Ota KT, Li XY, Sakaue F, Li N, Dutheil S, Banasr M, Duric V et al (2016) Psychological stress activates the Inflammasome via release of adenosine triphosphate and stimulation of the purinergic type 2X7 receptor. Biol Psychiatry 80(1):12–22. https://doi.org/10.1016/j.biopsych.2015.11.026 CrossRefPubMedPubMedCentralGoogle Scholar
- 108.Abbasi SH, Hosseini F, Modabbernia A, Ashrafi M, Akhondzadeh S (2012) Effect of celecoxib add-on treatment on symptoms and serum IL-6 concentrations in patients with major depressive disorder: randomized double-blind placebo-controlled study. J Affect Disord 141(2–3):308–314. https://doi.org/10.1016/j.jad.2012.03.033 CrossRefPubMedPubMedCentralGoogle Scholar
- 110.Muller N, Schwarz MJ, Dehning S, Douhe A, Cerovecki A, Goldstein-Muller B, Spellmann I, Hetzel G et al (2006) The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine. Mol Psychiatry 11(7):680–684. https://doi.org/10.1038/sj.mp.4001805 CrossRefPubMedPubMedCentralGoogle Scholar
- 111.Nery FG, Monkul ES, Hatch JP, Fonseca M, Zunta-Soares GB, Frey BN, Bowden CL, Soares JC (2008) Celecoxib as an adjunct in the treatment of depressive or mixed episodes of bipolar disorder: a double-blind, randomized, placebo-controlled study. Hum Psychopharmacol 23(2):87–94. https://doi.org/10.1002/hup.912 CrossRefPubMedPubMedCentralGoogle Scholar
- 113.Hayley S, Poulter MO, Merali Z, Anisman H (2005) The pathogenesis of clinical depression: stressor- and cytokine-induced alterations of neuroplasticity. Neuroscience 135(3):659–678. https://doi.org/10.1016/j.neuroscience.2005.03.051 CrossRefPubMedPubMedCentralGoogle Scholar
- 116.Licinio J, Wong ML (1999) The role of inflammatory mediators in the biology of major depression: central nervous system cytokines modulate the biological substrate of depressive symptoms, regulate stress-responsive systems, and contribute to neurotoxicity and neuroprotection. Mol Psychiatry 4(4):317–327CrossRefPubMedCentralGoogle Scholar
- 117.Drexhage RC, van der Heul-Nieuwenhuijsen L, Padmos RC, van Beveren N, Cohen D, Versnel MA, Nolen WA, Drexhage HA (2010) Inflammatory gene expression in monocytes of patients with schizophrenia: overlap and difference with bipolar disorder. A study in naturalistically treated patients. Int J Neuropsychopharmacol 13(10):1369–1381. https://doi.org/10.1017/S1461145710000799 CrossRefPubMedPubMedCentralGoogle Scholar
- 120.Rausch JL (2005) Initial conditions of psychotropic drug response: studies of serotonin transporter long promoter region (5-HTTLPR), serotonin transporter efficiency, cytokine and kinase gene expression relevant to depression and antidepressant outcome. Prog Neuro-Psychopharmacol Biol Psychiatry 29(6):1046–1061. https://doi.org/10.1016/j.pnpbp.2005.03.011 CrossRefGoogle Scholar
- 123.Rock KL, Latz E, Ontiveros F, Kono H (2010) The sterile inflammatory response. Annu Rev Immunol 28:321–342. https://doi.org/10.1146/annurev-immunol-030409-101311 CrossRefPubMedPubMedCentralGoogle Scholar
- 128.Kling MA, Alesci S, Csako G, Costello R, Luckenbaugh DA, Bonne O, Duncko R, Drevets WC et al (2007) Sustained low-grade pro-inflammatory state in unmedicated, remitted women with major depressive disorder as evidenced by elevated serum levels of the acute phase proteins C-reactive protein and serum amyloid A. Biol Psychiatry 62(4):309–313. https://doi.org/10.1016/j.biopsych.2006.09.033 CrossRefPubMedPubMedCentralGoogle Scholar
- 131.Capuron L, Schroecksnadel S, Feart C, Aubert A, Higueret D, Barberger-Gateau P, Laye S, Fuchs D (2011) Chronic low-grade inflammation in elderly persons is associated with altered tryptophan and tyrosine metabolism: role in neuropsychiatric symptoms. Biol Psychiatry 70(2):175–182. https://doi.org/10.1016/j.biopsych.2010.12.006 CrossRefPubMedPubMedCentralGoogle Scholar
- 135.Felger JC, Cole SW, Pace TW, Hu F, Woolwine BJ, Doho GH, Raison CL, Miller AH (2012) Molecular signatures of peripheral blood mononuclear cells during chronic interferon-alpha treatment: relationship with depression and fatigue. Psychol Med 42(8):1591–1603. https://doi.org/10.1017/S0033291711002868 CrossRefPubMedPubMedCentralGoogle Scholar
- 143.Song C, Halbreich U, Han C, Leonard BE, Luo H (2009) Imbalance between pro- and anti-inflammatory cytokines, and between Th1 and Th2 cytokines in depressed patients: the effect of electroacupuncture or fluoxetine treatment. Pharmacopsychiatry 42(5):182–188. https://doi.org/10.1055/s-0029-1202263 CrossRefPubMedPubMedCentralGoogle Scholar
- 148.Pannekoek JN, van der Werff SJ, van den Bulk BG, van Lang ND, Rombouts SA, van Buchem MA, Vermeiren RR, van der Wee NJ (2014) Reduced anterior cingulate gray matter volume in treatment-naive clinically depressed adolescents. Neuroimage Clin 4:336–342. https://doi.org/10.1016/j.nicl.2014.01.007 CrossRefPubMedPubMedCentralGoogle Scholar
- 150.Czeh B, Michaelis T, Watanabe T, Frahm J, de Biurrun G, van Kampen M, Bartolomucci A, Fuchs E (2001) Stress-induced changes in cerebral metabolites, hippocampal volume, and cell proliferation are prevented by antidepressant treatment with tianeptine. Proc Natl Acad Sci U S A 98(22):12796–12801. https://doi.org/10.1073/pnas.211427898 CrossRefPubMedPubMedCentralGoogle Scholar
- 152.Piccinni A, Marazziti D, Catena M, Domenici L, Del Debbio A, Bianchi C, Mannari C, Martini C et al (2008) Plasma and serum brain-derived neurotrophic factor (BDNF) in depressed patients during 1 year of antidepressant treatments. J Affect Disord 105(1–3):279–283. https://doi.org/10.1016/j.jad.2007.05.005 CrossRefPubMedPubMedCentralGoogle Scholar
- 153.Mohle L, Mattei D, Heimesaat MM, Bereswill S, Fischer A, Alutis M, French T, Hambardzumyan D et al (2016) Ly6C(hi) monocytes provide a link between antibiotic-induced changes in gut microbiota and adult hippocampal neurogenesis. Cell Rep 15(9):1945–1956. https://doi.org/10.1016/j.celrep.2016.04.074 CrossRefPubMedPubMedCentralGoogle Scholar
- 155.Maes M, Galecki P, Chang YS, Berk M (2011) A review on the oxidative and nitrosative stress (O&NS) pathways in major depression and their possible contribution to the (neuro)degenerative processes in that illness. Prog Neuro-Psychopharmacol Biol Psychiatry 35(3):676–692. https://doi.org/10.1016/j.pnpbp.2010.05.004 CrossRefGoogle Scholar
- 160.Sarandol A, Sarandol E, Eker SS, Erdinc S, Vatansever E, Kirli S (2007) Major depressive disorder is accompanied with oxidative stress: short-term antidepressant treatment does not alter oxidative-antioxidative systems. Hum Psychopharmacol 22(2):67–73. https://doi.org/10.1002/hup.829 CrossRefGoogle Scholar
- 161.Forlenza MJ, Miller GE (2006) Increased serum levels of 8-hydroxy-2′-deoxyguanosine in clinical depression. Psychosom Med 68(1):1–7. https://doi.org/10.1097/01.psy.0000195780.37277.2a CrossRefPubMedPubMedCentralGoogle Scholar
- 162.Maes M, Mihaylova I, Leunis JC (2007) Increased serum IgM antibodies directed against phosphatidyl inositol (Pi) in chronic fatigue syndrome (CFS) and major depression: evidence that an IgM-mediated immune response against Pi is one factor underpinning the comorbidity between both CFS and depression. Neuro Endocrinol Lett 28(6):861–867PubMedPubMedCentralGoogle Scholar
- 163.Maes M, Mihaylova I, Kubera M, Leunis JC (2008) An IgM-mediated immune response directed against nitro-bovine serum albumin (nitro-BSA) in chronic fatigue syndrome (CFS) and major depression: evidence that nitrosative stress is another factor underpinning the comorbidity between major depression and CFS. Neuro Endocrinol Lett 29(3):313–319PubMedPubMedCentralGoogle Scholar
- 164.Kotan VO, Sarandol E, Kirhan E, Ozkaya G, Kirli S (2011) Effects of long-term antidepressant treatment on oxidative status in major depressive disorder: a 24-week follow-up study. Prog Neuro-Psychopharmacol Biol Psychiatry 35(5):1284–1290. https://doi.org/10.1016/j.pnpbp.2011.03.021 CrossRefGoogle Scholar
- 165.Tsuboi H, Shimoi K, Kinae N, Oguni I, Hori R, Kobayashi F (2004) Depressive symptoms are independently correlated with lipid peroxidation in a female population: comparison with vitamins and carotenoids. J Psychosom Res 56(1):53–58. https://doi.org/10.1016/S0022-3999(03)00567-1 CrossRefGoogle Scholar
- 176.Goshen I, Kreisel T, Ben-Menachem-Zidon O, Licht T, Weidenfeld J, Ben-Hur T, Yirmiya R (2008) Brain interleukin-1 mediates chronic stress-induced depression in mice via adrenocortical activation and hippocampal neurogenesis suppression. Mol Psychiatry 13(7):717–728. https://doi.org/10.1038/sj.mp.4002055 CrossRefGoogle Scholar
- 178.Too LK, Mitchell AJ, Yau B, Ball HJ, McGregor IS, Hunt NH (2014) Interleukin-18 deficiency and its long-term behavioural and cognitive impacts in a murine model of pneumococcal meningitis. Behav Brain Res 263:176–189. https://doi.org/10.1016/j.bbr.2014.01.035 CrossRefPubMedPubMedCentralGoogle Scholar
- 179.Sugama S, Wirz SA, Barr AM, Conti B, Bartfai T, Shibasaki T (2004) Interleukin-18 null mice show diminished microglial activation and reduced dopaminergic neuron loss following acute 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment. Neuroscience 128(2):451–458. https://doi.org/10.1016/j.neuroscience.2004.07.020 CrossRefPubMedPubMedCentralGoogle Scholar
- 180.Sugama S, Fujita M, Hashimoto M, Conti B (2007) Stress induced morphological microglial activation in the rodent brain: involvement of interleukin-18. Neuroscience 146(3):1388–1399. https://doi.org/10.1016/j.neuroscience.2007.02.043 CrossRefPubMedPubMedCentralGoogle Scholar
- 187.Ganter MT, Ware LB, Howard M, Roux J, Gartland B, Matthay MA, Fleshner M, Pittet JF (2006) Extracellular heat shock protein 72 is a marker of the stress protein response in acute lung injury. Am J Physiol Lung Cell Mol Physiol 291(3):L354–L361. https://doi.org/10.1152/ajplung.00405.2005 CrossRefPubMedPubMedCentralGoogle Scholar
- 192.Dinarello CA (2009) Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol 27:519–550. https://doi.org/10.1146/annurev.immunol.021908.132612 CrossRefGoogle Scholar
- 194.Lawson MA, McCusker RH, Kelley KW (2013) Interleukin-1 beta converting enzyme is necessary for development of depression-like behavior following intracerebroventricular administration of lipopolysaccharide to mice. J Neuroinflammation 10:54. https://doi.org/10.1186/1742-2094-10-54 CrossRefPubMedPubMedCentralGoogle Scholar
- 196.Mastronardi CA, Paz-Filho G, Zanoni M, Molano-Gonzalez N, Arcos-Burgos M, Licinio J, Wong ML (2015) Temporal gene expression in the hippocampus and peripheral organs to endotoxin-induced systemic inflammatory response in caspase-1-deficient mice. Neuroimmunomodulation 22(4):263–273. https://doi.org/10.1159/000368310 CrossRefPubMedPubMedCentralGoogle Scholar
- 202.Galecki P, Galecka E, Maes M, Chamielec M, Orzechowska A, Bobinska K, Lewinski A, Szemraj J (2012) The expression of genes encoding for COX-2, MPO, iNOS, and sPLA2-IIA in patients with recurrent depressive disorder. J Affect Disord 138(3):360–366. https://doi.org/10.1016/j.jad.2012.01.016 CrossRefPubMedPubMedCentralGoogle Scholar
- 203.Galecki P, Maes M, Florkowski A, Lewinski A, Galecka E, Bienkiewicz M, Szemraj J (2010) An inducible nitric oxide synthase polymorphism is associated with the risk of recurrent depressive disorder. Neurosci Lett 486(3):184–187. https://doi.org/10.1016/j.neulet.2010.09.048 CrossRefPubMedPubMedCentralGoogle Scholar
- 204.Maes M, Kubera M, Mihaylova I, Geffard M, Galecki P, Leunis JC, Berk M (2013) Increased autoimmune responses against auto-epitopes modified by oxidative and nitrosative damage in depression: implications for the pathways to chronic depression and neuroprogression. J Affect Disord 149(1–3):23–29. https://doi.org/10.1016/j.jad.2012.06.039 CrossRefGoogle Scholar
- 205.Maes M, Mihaylova I, Kubera M, Leunis JC, Geffard M (2011) IgM-mediated autoimmune responses directed against multiple neoepitopes in depression: new pathways that underpin the inflammatory and neuroprogressive pathophysiology. J Affect Disord 135(1–3):414–418. https://doi.org/10.1016/j.jad.2011.08.023 CrossRefPubMedPubMedCentralGoogle Scholar
- 210.Bersudsky M, Luski L, Fishman D, White RM, Ziv-Sokolovskaya N, Dotan S, Rider P, Kaplanov I et al (2014) Non-redundant properties of IL-1alpha and IL-1beta during acute colon inflammation in mice. Gut 63(4):598–609. https://doi.org/10.1136/gutjnl-2012-303329 CrossRefPubMedPubMedCentralGoogle Scholar
- 217.Yamamoto Y, Tanahashi T, Katsuura S, Kurokawa K, Nishida K, Kuwano Y, Kawai T, Teshima-Kondo S et al (2010) Interleukin-18 deficiency reduces neuropeptide gene expressions in the mouse amygdala related with behavioral change. J Neuroimmunol 229(1–2):129–139. https://doi.org/10.1016/j.jneuroim.2010.07.024 CrossRefPubMedPubMedCentralGoogle Scholar
- 221.Schmitz J, Owyang A, Oldham E, Song Y, Murphy E, McClanahan TK, Zurawski G, Moshrefi M et al (2005) IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 23(5):479–490. https://doi.org/10.1016/j.immuni.2005.09.015 CrossRefGoogle Scholar
- 226.Liu RP, Zou M, Wang JY, Zhu JJ, Lai JM, Zhou LL, Chen SF, Zhang X et al (2014) Paroxetine ameliorates lipopolysaccharide-induced microglia activation via differential regulation of MAPK signaling. J Neuroinflammation 11:47. https://doi.org/10.1186/1742-2094-11-47 CrossRefPubMedPubMedCentralGoogle Scholar
- 233.Ikenouchi-Sugita A, Yoshimura R, Hori H, Umene-Nakano W, Ueda N, Nakamura J (2009) Effects of antidepressants on plasma metabolites of nitric oxide in major depressive disorder: comparison between milnacipran and paroxetine. Prog Neuro-Psychopharmacol Biol Psychiatry 33(8):1451–1453. https://doi.org/10.1016/j.pnpbp.2009.07.028 CrossRefGoogle Scholar
- 236.Rivera-Chavez F, Zhang LF, Faber F, Lopez CA, Byndloss MX, Olsan EE, Xu G, Velazquez EM et al (2016) Depletion of butyrate-producing clostridia from the gut microbiota drives an aerobic luminal expansion of salmonella. Cell Host Microbe 19(4):443–454. https://doi.org/10.1016/j.chom.2016.03.004 CrossRefPubMedPubMedCentralGoogle Scholar
- 237.Byndloss MX, Olsan EE, Rivera-Chavez F, Tiffany CR, Cevallos SA, Lokken KL, Torres TP, Byndloss AJ et al (2017) Microbiota-activated PPAR-gamma signaling inhibits dysbiotic Enterobacteriaceae expansion. Science 357(6351):570–575. https://doi.org/10.1126/science.aam9949 CrossRefPubMedPubMedCentralGoogle Scholar
- 238.Klena J, Zhang P, Schwartz O, Hull S, Chen T (2005) The core lipopolysaccharide of Escherichia coli is a ligand for the dendritic-cell-specific intercellular adhesion molecule nonintegrin CD209 receptor. J Bacteriol 187(5):1710–1715. https://doi.org/10.1128/JB.187.5.1710-1715.2005 CrossRefPubMedPubMedCentralGoogle Scholar
- 246.Schneider WM, Chevillotte MD, Rice CM (2014) Interferon-stimulated genes: a complex web of host defenses. Annu Rev Immunol 32:513–545. https://doi.org/10.1146/annurev-immunol-032713-120231 CrossRefPubMedPubMedCentralGoogle Scholar
- 252.Maes M, Scharpe S, Meltzer HY, Okayli G, Bosmans E, D'Hondt P, Vanden Bossche BV, Cosyns P (1994) Increased neopterin and interferon-gamma secretion and lower availability of L-tryptophan in major depression: further evidence for an immune response. Psychiatry Res 54(2):143–160CrossRefPubMedCentralGoogle Scholar
- 253.Kahl KG, Kruse N, Faller H, Weiss H, Rieckmann P (2002) Expression of tumor necrosis factor-alpha and interferon-gamma mRNA in blood cells correlates with depression scores during an acute attack in patients with multiple sclerosis. Psychoneuroendocrinology 27(6):671–681CrossRefPubMedCentralGoogle Scholar
- 255.Maes M, Song C, Lin AH, Bonaccorso S, Kenis G, De Jongh R, Bosmans E, Scharpe S (1999) Negative immunoregulatory effects of antidepressants: inhibition of interferon-gamma and stimulation of interleukin-10 secretion. Neuropsychopharmacology 20(4):370–379. https://doi.org/10.1016/S0893-133X(98)00088-8 CrossRefPubMedPubMedCentralGoogle Scholar
- 256.Myint AM, Bondy B, Baghai TC, Eser D, Nothdurfter C, Schule C, Zill P, Muller N et al (2013) Tryptophan metabolism and immunogenetics in major depression: a role for interferon-gamma gene. Brain Behav Immun 31:128–133. https://doi.org/10.1016/j.bbi.2013.04.003 CrossRefPubMedPubMedCentralGoogle Scholar
- 257.Raitala A, Pertovaara M, Karjalainen J, Oja SS, Hurme M (2005) Association of interferon-gamma +874(T/a) single nucleotide polymorphism with the rate of tryptophan catabolism in healthy individuals. Scand J Immunol 61(4):387–390. https://doi.org/10.1111/j.1365-3083.2005.01586.x CrossRefPubMedPubMedCentralGoogle Scholar
- 259.O'Connor JC, Andre C, Wang Y, Lawson MA, Szegedi SS, Lestage J, Castanon N, Kelley KW et al (2009) Interferon-gamma and tumor necrosis factor-alpha mediate the upregulation of indoleamine 2,3-dioxygenase and the induction of depressive-like behavior in mice in response to bacillus Calmette-Guerin. J Neurosci 29(13):4200–4209. https://doi.org/10.1523/JNEUROSCI.5032-08.2009 CrossRefPubMedPubMedCentralGoogle Scholar
- 262.Smeltz RB, Chen J, Ehrhardt R, Shevach EM (2002) Role of IFN-gamma in Th1 differentiation: IFN-gamma regulates IL-18R alpha expression by preventing the negative effects of IL-4 and by inducing/maintaining IL-12 receptor beta 2 expression. J Immunol 168(12):6165–6172CrossRefPubMedCentralGoogle Scholar
- 264.Litteljohn D, Cummings A, Brennan A, Gill A, Chunduri S, Anisman H, Hayley S (2010) Interferon-gamma deficiency modifies the effects of a chronic stressor in mice: implications for psychological pathology. Brain Behav Immun 24(3):462–473. https://doi.org/10.1016/j.bbi.2009.12.001 CrossRefPubMedPubMedCentralGoogle Scholar
- 265.Campos AC, Vaz GN, Saito VM, Teixeira AL (2014) Further evidence for the role of interferon-gamma on anxiety- and depressive-like behaviors: involvement of hippocampal neurogenesis and NGF production. Neurosci Lett 578:100–105. https://doi.org/10.1016/j.neulet.2014.06.039 CrossRefPubMedPubMedCentralGoogle Scholar
Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.